View Older Stories
-
Surgery Partners (SGRY) PT Lowered at RBC Capital as 2026 Guide Prompts Selloff
-
Benchmark Reiterates Buy Rating on Surgery Partners (SGRY) Following Q4 Results
-
After-hours movers: MongoDB, Credo, SoFi Technologies and more
-
Surgery Partners, Inc. (SGRY) Misses Q4 EPS by 18c; offers guidance
-
Surgery Partners prices $425 million add-on notes offering
-
Surgery Partners (SGRY) PT Lowered to $22 at Mizuho
-
Surgery Partners (SGRY) PT Lowered to $29 at UBS
-
Surgery Partners (SGRY) PT Lowered to $30 at Benchmark
-
Surgery Partners (SGRY) PT Lowered at RBC Capital; 'Selloff Overdone'
-
Surgery Partners (SGRY) PT Lowered to $24 at BofA Securities
-
Surgery Partners, Inc. (SGRY) Misses Q3 EPS by 8c, provides guidance
-
Surgery Partners (SGRY): Q3 survey results more positive than guidance, says analyst
-
Cantor Fitzgerald Reiterates Neutral Rating on Acadia Healthcare (ACHC)
-
Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY)
-
JPMorgan Assumes Surgery Partners (SGRY) at Neutral
-
Surgery Partners executive Harrison Bane to resign October 3
-
Benchmark Reiterates Buy Rating on Surgery Partners (SGRY)
-
Surgery Partners, Inc. (SGRY) Tops Q2 EPS by 1c ; Offers Guidance
-
BofA Securities Resumes Surgery Partners (SGRY) to Buy
-
Benchmark Reiterates Buy Rating on Surgery Partners (SGRY)
-
Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY)
-
UBS Reiterates Buy Rating on Surgery Partners (SGRY)
-
UBS Reiterates Buy Rating on Surgery Partners (SGRY)
-
Surgery Partners (SGRY) guidance reaffirmation 'positive' despite no Bain deal - Mizuho
-
Leerink Partners thesis on Surgery Partners (SGRY) 'unchanged' as Bain deal collapses
-
Surgery Partners (SGRY) and Bain Capital Conclude Discussions
-
UBS Reiterates Buy Rating on Surgery Partners (SGRY)
-
Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY)
-
KeyBanc Reiterates Sector Weight Rating on Surgery Partners (SGRY)
-
Benchmark Reiterates Buy Rating on Surgery Partners (SGRY)
-
Surgery Partners (SGRY) PT Lowered to $34 at Leerink Partners
-
Surgery Partners, Inc. (SGRY) Misses Q1 EPS by 4c, provides guidance
-
Benchmark Reiterates Buy Rating on Surgery Partners (SGRY)
-
Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY)
-
Given contract opportunity Caid stocks likely undervalued, says Cantor Fitzgerald
-
Surgery Partners (SGRY) PT Lowered to $35 at Benchmark
-
KeyBanc on Surgery Partners (SGRY): 'Solid Finish, Bain Offer Remains the NT Focus for the Stock'
-
Surgery Partners (SGRY) PT Lowered to $34 at UBS
-
Surgery Partners, Inc. (SGRY) Tops Q4 EPS by 5c ; Offers Guidance
-
Cantor Fitzgerald Reiterates Overweight Rating on Surgery Partners (SGRY)
-
Surgery Partners, Inc. (SGRY) Confirms Receipt of Non-Binding $25.75/sh Acquisition Proposal from Bain Capital
-
Surgery Partners, Inc. (SGRY) Receives Takeover Offer from BCPE
-
Surgery Partners, Inc. (SGRY) Appoints Laura L. Forese to its Board
-
BofA Securities Starts Surgery Partners (SGRY) at Buy
-
Surgery Partners (SGRY) PT Lowered to $35 at RBC Capital
-
Surgery Partners (SGRY) PT Lowered to $32 at TD Cowen
-
Surgery Partners (SGRY) PT Lowered to $40 at Jefferies
-
Surgery Partners (SGRY) PT Lowered to $31 at Barclays
-
Surgery Partners, Inc. (SGRY) Misses Q3 EPS by 6c; reaffirms guidance
-
Surgery Partners (SGRY) on watch on chatter

